AlphaQuest LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 127.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,109 shares of the biopharmaceutical company's stock after buying an additional 10,709 shares during the period. AlphaQuest LLC's holdings in Gilead Sciences were worth $1,765,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently modified their holdings of the company. Bellevue Group AG increased its holdings in Gilead Sciences by 18.2% during the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company's stock valued at $3,859,000 after purchasing an additional 7,093 shares in the last quarter. Quantinno Capital Management LP increased its stake in shares of Gilead Sciences by 149.5% in the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company's stock valued at $6,843,000 after buying an additional 48,910 shares in the last quarter. McAdam LLC raised its holdings in shares of Gilead Sciences by 16.7% in the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock valued at $2,344,000 after buying an additional 3,627 shares during the last quarter. Capital Investment Advisors LLC lifted its position in Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company's stock worth $35,793,000 after buying an additional 9,791 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its holdings in Gilead Sciences by 3.9% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company's stock worth $13,132,000 after acquiring an additional 5,382 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.
Insider Buying and Selling
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares of the company's stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 293,356 shares of company stock valued at $29,166,240. Company insiders own 0.16% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the stock. Mizuho boosted their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a research note on Thursday, November 21st. The Goldman Sachs Group boosted their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Bank of America upped their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Oppenheimer lifted their target price on Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research note on Tuesday, March 4th. Finally, Piper Sandler upped their price target on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $104.52.
View Our Latest Analysis on GILD
Gilead Sciences Trading Down 2.3 %
Shares of Gilead Sciences stock traded down $2.69 during trading hours on Tuesday, hitting $114.52. The company's stock had a trading volume of 7,935,973 shares, compared to its average volume of 8,169,864. The company has a market capitalization of $142.62 billion, a PE ratio of 309.52, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a 50 day moving average of $100.12 and a 200 day moving average of $91.91. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a $0.79 dividend. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.76%. The ex-dividend date is Friday, March 14th. Gilead Sciences's payout ratio is currently 854.05%.
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
